Calcium Chloride

Identification

Name
Calcium Chloride
Accession Number
DB01164  (APRD00840)
Type
Small Molecule
Groups
Approved
Description

Calcium chloride is an ionic compound of calcium and chlorine. It is highly soluble in water and it is deliquescent. It is a salt that is solid at room temperature, and it behaves as a typical ionic halide. It has several common applications such as brine for refrigeration plants, ice and dust control on roads, and in cement. It can be produced directly from limestone, but large amounts are also produced as a by-product of the Solvay process. Because of its hygroscopic nature, it must be kept in tightly-sealed containers. [Wikipedia]

Structure
Thumb
Synonyms
  • Calcium chloride anhydrous
  • Calcium chloride, anhydrous
  • calcium(2+) chloride
External IDs
E-509 / INS NO.509 / INS-509
Product Ingredients
IngredientUNIICASInChI Key
Calcium chloride dihydrateM4I0D6VV5M10035-04-8LLSDKQJKOVVTOJ-UHFFFAOYSA-L
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Calciject Inj 100mg/mlLiquid100 mgIntravenousOmega Laboratories Ltd1990-12-31Not applicableCanada
Calcium ChlorideInjection, solution100 mg/mLIntravenousCardinal Health2011-03-09Not applicableUs
Calcium ChlorideInjection, solution100 mg/mLIntravenousMedical Purchasing Solutions, Llc2005-09-14Not applicableUs
Calcium ChlorideInjection, solution100 mg/mLIntravenousGeneral Injectables & Vaccines2010-07-01Not applicableUs
Calcium ChlorideInjection, solution100 mg/mLIntravenousHospira, Inc.2005-09-14Not applicableUs
Calcium Chloride Additive 0.13-4.5lPowder3.78 gHemodialysisHaemotec Inc.2006-12-012011-07-27Canada
Calcium Chloride Bp - Additive for Concentrated Haemodialysis SolutionsPowder3.78 gHemodialysisGenpharm Ulc1998-06-182004-07-30Canada
Calcium Chloride Bp - Additive for Concentrated Haemodialysis SolutionsPowder12.32 gHemodialysisGenpharm Ulc1998-06-182004-07-30Canada
Calcium Chloride for HaemodialysisPowder7.45 gHemodialysisChief Medical Supplies Ltd2013-03-26Not applicableCanada
Calcium Chloride Inj 10%Liquid100 mgIntravenousInternational Medication Systems, Limited1971-12-311997-08-15Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Calcium ChlorideInjection, solution100 mg/mLIntravenousAmerican Regent2018-02-06Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
(40 Mmols/l) Potassium Chloride In Lactated Ringer's Injection USPCalcium Chloride (20 mg) + Sodium lactate (310 mg) + Potassium Chloride (328 mg) + Sodium Chloride (600 mg)SolutionIntravenousBaxter Laboratories2002-12-112016-07-15Canada
5% Dextrose In Lactated Ringer's InjectionCalcium Chloride (20 mg) + Dextrose, unspecified form (5 g) + Sodium lactate (310 mg) + Potassium Chloride (30 mg) + Sodium Chloride (600 mg)SolutionIntravenousB. Braun Medical Inc.1993-12-31Not applicableCanada
Accusol 35 K0Calcium Chloride (0.343 g) + Magnesium chloride (0.136 g) + Sodium Chloride (7.66 g) + Sodium bicarbonate (12.9 g)SolutionHemodialysisChief Medical Supplies Ltd2007-10-31Not applicableCanada
Accusol 35 K2Calcium Chloride (0.343 g) + D-glucose (1.33 g) + Magnesium chloride (0.136 g) + Potassium Chloride (0.199 g) + Sodium Chloride (7.66 g) + Sodium bicarbonate (12.9 g)SolutionHemodialysisChief Medical Supplies LtdNot applicableNot applicableCanada
Accusol 35 K4Calcium Chloride (0.343 g) + D-glucose (1.33 g) + Magnesium chloride (0.136 g) + Potassium Chloride (0.398 g) + Sodium Chloride (7.66 g) + Sodium bicarbonate (12.9 g)SolutionHemodialysisChief Medical Supplies Ltd2007-10-31Not applicableCanada
Acetate Concentrate R07376Calcium Chloride (6.432 g) + Dextrose, unspecified form (38.5 g) + Magnesium chloride (3.558 g) + Potassium Chloride (2.609 g) + Sodium Chloride (204.5 g) + Sodium acetate (114.8 g)LiquidHemodialysisBdh Inc.1995-12-312000-08-03Canada
Acid Concentrate D12028Calcium Chloride (7.16 g) + Acetic acid (8.85 g) + Magnesium chloride (0.88 g) + Potassium Chloride (2.75 g) + Sodium Chloride (172 g)LiquidHemodialysisAlthin Biopharm Inc.1986-12-311997-08-13Canada
Acid Concentrate D12054Calcium Chloride (6.13 g) + Acetic acid (8.85 g) + Magnesium chloride (2.63 g) + Potassium Chloride (5.49 g) + Sodium Chloride (172.2 g)LiquidHemodialysisAlthin Biopharm Inc.1986-12-311997-08-13Canada
Acid Concentrate D12092Calcium Chloride (7.49 g) + Acetic acid (5.41 g) + Magnesium chloride (3.21 g) + Potassium Chloride (5.02 g) + Sodium Chloride (263 g)SolutionHemodialysisAlthin Biopharm Inc.1985-12-311998-08-27Canada
Acid Concentrate D12093Calcium Chloride (7.49 g) + Acetic acid (5.41 g) + Magnesium chloride (3.21 g) + Potassium Chloride (10.1 g) + Sodium Chloride (263 g)LiquidHemodialysisBaxter Laboratories1985-12-312002-08-01Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Calcium ChlorideCalcium Chloride (100 mg/mL)InjectionIntravenous; IntraventricularMedical Purchasing Solutions, Llc1973-05-01Not applicableUs
Calcium ChlorideCalcium Chloride (100 mg/mL)InjectionIntravenous; IntraventricularA S Medication Solutions1973-05-012017-06-20Us
Calcium ChlorideCalcium Chloride (100 mg/mL)Injection, solutionIntravenous; IntraventricularCardinal Health1984-09-17Not applicableUs
Calcium ChlorideCalcium Chloride (100 mg/mL)InjectionParenteralAmphastar Pharmaceuticals, Inc.2000-06-012016-12-07Us
Calcium ChlorideCalcium Chloride (100 mg/mL)InjectionIntravenous; IntraventricularInternational Medication Systems, Limited1973-05-01Not applicableUs
Calcium ChlorideCalcium Chloride (100 mg/mL)Injection, solutionIntravenousGeneral Injectables & Vaccines2010-03-012017-01-19Us
Calcium ChlorideCalcium Chloride (100 mg/mL)Injection, solutionIntravenous; IntraventricularHospira, Inc.1984-09-17Not applicableUs
Calcium ChlorideCalcium Chloride (100 mg/mL)Injection, solutionIntravenous; IntraventricularGeneral Injectables & Vaccines2010-03-01Not applicableUs
Calcium ChlorideCalcium Chloride (100 mg/mL)InjectionIntravenousCardinal Health2011-06-142018-05-31Us
Calcium ChlorideCalcium Chloride (20 mg/mL)Injection, solutionIntravenousCantrell Drug Company2011-03-08Not applicableUs
International/Other Brands
Jarcal / LiquiCal-D 400
Categories
UNII
OFM21057LP
CAS number
10043-52-4
Weight
Average: 110.984
Monoisotopic: 109.900296569
Chemical Formula
CaCl2
InChI Key
UXVMQQNJUSDDNG-UHFFFAOYSA-L
InChI
InChI=1S/Ca.2ClH/h;2*1H/q+2;;/p-2
IUPAC Name
calcium dichloride
SMILES
[Cl-].[Cl-].[Ca++]

Pharmacology

Indication

For the treatment of hypocalcemia in those conditions requiring a prompt increase in blood plasma calcium levels, for the treatment of magnesium intoxication due to overdosage of magnesium sulfate, and used to combat the deleterious effects of hyperkalemia as measured by electrocardiographic (ECG), pending correction of the increased potassium level in the extracellular fluid.

Associated Conditions
Associated Therapies
Pharmacodynamics

Calcium is the fifth most abundant element in the body and the major fraction is in the bony structure. Calcium plays important physiological roles, many of which are poorly understood. It is essential for the functional integrity of the nervous and muscular systems. It is necessary for normal cardiac function and is one of the factors that operates in the mechanisms involved in the coagulation of blood.

Mechanism of action

Calcium chloride in water dissociates to provide calcium (Ca2+) and chloride (Cl-) ions. They are normal constituents of the body fluids and are dependent on various physiological mechanisms for maintenance of balance between intake and output. For hyperkalemia, the influx of calcium helps restore the normal gradient between threshold potential and resting membrane potential.

TargetActionsOrganism
UProtein S100-A13Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Approximately 80% of body calcium is excreted in the feces as insoluble salts; urinary excretion accounts for the remaining 20%.

Route of elimination

Approximately 80% of body calcium is excreted in the feces as insoluble salts; urinary excretion accounts for the remaining 20%.

Half life
Not Available
Clearance
Not Available
Toxicity

Too rapid injection may produce lowering of blood pressure and cardiac syncope. Persistent hypercalcemia from overdosage of calcium is unlikely because of rapid excretion.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinCalcium Chloride may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AcetyldigoxinCalcium Chloride may increase the arrhythmogenic activities of Acetyldigoxin.Experimental
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Calcium Chloride.Experimental, Investigational
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Calcium Chloride.Approved
AlfacalcidolThe risk or severity of adverse effects can be increased when Calcium Chloride is combined with Alfacalcidol.Approved, Nutraceutical
AmiodaroneThe therapeutic efficacy of Amiodarone can be decreased when used in combination with Calcium Chloride.Approved, Investigational
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium Chloride.Approved
AmrinoneThe therapeutic efficacy of Amrinone can be decreased when used in combination with Calcium Chloride.Approved
AranidipineThe therapeutic efficacy of Aranidipine can be decreased when used in combination with Calcium Chloride.Approved, Investigational
AzelnidipineThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium Chloride.Approved, Investigational
AzimilideThe therapeutic efficacy of Azimilide can be decreased when used in combination with Calcium Chloride.Investigational
BarnidipineThe therapeutic efficacy of Barnidipine can be decreased when used in combination with Calcium Chloride.Approved
BencyclaneThe therapeutic efficacy of Bencyclane can be decreased when used in combination with Calcium Chloride.Experimental
BendroflumethiazideBendroflumethiazide may decrease the excretion rate of Calcium Chloride which could result in a higher serum level.Approved
BenidipineThe therapeutic efficacy of Benidipine can be decreased when used in combination with Calcium Chloride.Approved, Investigational
BenzthiazideBenzthiazide may decrease the excretion rate of Calcium Chloride which could result in a higher serum level.Approved
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium Chloride.Approved, Withdrawn
BioallethrinThe therapeutic efficacy of Bioallethrin can be decreased when used in combination with Calcium Chloride.Approved, Experimental
CalcidiolThe risk or severity of adverse effects can be increased when Calcium Chloride is combined with Calcidiol.Approved, Nutraceutical
CalcipotriolThe risk or severity of adverse effects can be increased when Calcium Chloride is combined with Calcipotriol.Approved
CalcitriolThe risk or severity of adverse effects can be increased when Calcium Chloride is combined with Calcitriol.Approved, Nutraceutical
Calcium AcetateThe risk or severity of adverse effects can be increased when Calcium Chloride is combined with Calcium Acetate.Approved, Investigational
CarboxyamidotriazoleThe therapeutic efficacy of Carboxyamidotriazole can be decreased when used in combination with Calcium Chloride.Investigational
CaroverineThe therapeutic efficacy of Caroverine can be decreased when used in combination with Calcium Chloride.Experimental
CeftriaxoneThe risk or severity of adverse effects can be increased when Calcium Chloride is combined with Ceftriaxone.Approved
ChlorothiazideChlorothiazide may decrease the excretion rate of Calcium Chloride which could result in a higher serum level.Approved, Vet Approved
ChlortetracyclineThe serum concentration of Chlortetracycline can be decreased when it is combined with Calcium Chloride.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may decrease the excretion rate of Calcium Chloride which could result in a higher serum level.Approved
CholecalciferolThe risk or severity of adverse effects can be increased when Calcium Chloride is combined with Cholecalciferol.Approved, Nutraceutical
CilnidipineThe therapeutic efficacy of Cilnidipine can be decreased when used in combination with Calcium Chloride.Approved, Investigational
CinnarizineThe therapeutic efficacy of Cinnarizine can be decreased when used in combination with Calcium Chloride.Approved, Investigational
CinoxacinCalcium Chloride can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
CiprofloxacinCalcium Chloride can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ClevidipineThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium Chloride.Approved, Investigational
Clodronic AcidThe serum concentration of Clodronic Acid can be decreased when it is combined with Calcium Chloride.Approved, Investigational, Vet Approved
CyclandelateThe therapeutic efficacy of Cyclandelate can be decreased when used in combination with Calcium Chloride.Approved
CyclopenthiazideCyclopenthiazide may decrease the excretion rate of Calcium Chloride which could result in a higher serum level.Experimental
CymarinCalcium Chloride may increase the arrhythmogenic activities of Cymarin.Experimental
DarodipineThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium Chloride.Experimental
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Calcium Chloride.Approved
DemeclocyclineThe serum concentration of Demeclocycline can be decreased when it is combined with Calcium Chloride.Approved
DeslanosideCalcium Chloride may increase the arrhythmogenic activities of Deslanoside.Approved
DexniguldipineThe therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Calcium Chloride.Experimental
DexverapamilThe therapeutic efficacy of Dexverapamil can be decreased when used in combination with Calcium Chloride.Experimental
DigitoxinCalcium Chloride may increase the arrhythmogenic activities of Digitoxin.Approved, Investigational
DigoxinCalcium Chloride may increase the arrhythmogenic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Calcium Chloride may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).Approved
DihydrotachysterolThe risk or severity of adverse effects can be increased when Calcium Chloride is combined with Dihydrotachysterol.Approved
DiltiazemThe therapeutic efficacy of Diltiazem can be decreased when used in combination with Calcium Chloride.Approved, Investigational
Dipotassium phosphateCalcium Chloride can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DobutamineThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium Chloride.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Calcium Chloride.Approved
DotarizineThe therapeutic efficacy of Dotarizine can be decreased when used in combination with Calcium Chloride.Investigational
DoxercalciferolThe risk or severity of adverse effects can be increased when Calcium Chloride is combined with Doxercalciferol.Approved
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Calcium Chloride.Approved, Investigational, Vet Approved
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium Chloride.Approved, Investigational
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Calcium Chloride.Approved
EmopamilThe therapeutic efficacy of Emopamil can be decreased when used in combination with Calcium Chloride.Experimental
EnoxacinCalcium Chloride can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EperisoneThe therapeutic efficacy of Eperisone can be decreased when used in combination with Calcium Chloride.Approved, Investigational
EpitizideEpitizide may decrease the excretion rate of Calcium Chloride which could result in a higher serum level.Experimental
ErgocalciferolThe risk or severity of adverse effects can be increased when Calcium Chloride is combined with Ergocalciferol.Approved, Nutraceutical
EstramustineCalcium Chloride can cause a decrease in the absorption of Estramustine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Calcium Chloride.Approved
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Calcium Chloride.Approved
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Chloride.Approved, Investigational
FendilineThe therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium Chloride.Withdrawn
Fish oilThe therapeutic efficacy of Fish oil can be decreased when used in combination with Calcium Chloride.Approved, Nutraceutical
FleroxacinCalcium Chloride can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FlumequineCalcium Chloride can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
FlunarizineThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Calcium Chloride.Approved
FluspirileneThe therapeutic efficacy of Fluspirilene can be decreased when used in combination with Calcium Chloride.Approved, Investigational
GabapentinThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Calcium Chloride.Approved, Investigational
GallopamilThe therapeutic efficacy of Gallopamil can be decreased when used in combination with Calcium Chloride.Investigational
GarenoxacinCalcium Chloride can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
GatifloxacinCalcium Chloride can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GemifloxacinCalcium Chloride can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GitoformateCalcium Chloride may increase the arrhythmogenic activities of Gitoformate.Experimental
GrepafloxacinCalcium Chloride can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
HydrochlorothiazideHydrochlorothiazide may decrease the excretion rate of Calcium Chloride which could result in a higher serum level.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may decrease the excretion rate of Calcium Chloride which could result in a higher serum level.Approved, Investigational
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium Chloride.Approved, Investigational
IndapamideIndapamide may decrease the excretion rate of Calcium Chloride which could result in a higher serum level.Approved
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Calcium Chloride.Approved, Investigational
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium Chloride.Approved, Investigational
LamotrigineThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium Chloride.Approved, Investigational
Lanatoside CCalcium Chloride may increase the arrhythmogenic activities of Lanatoside C.Experimental
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium Chloride.Approved, Investigational
LevetiracetamThe therapeutic efficacy of Levetiracetam can be decreased when used in combination with Calcium Chloride.Approved, Investigational
LevofloxacinCalcium Chloride can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Calcium Chloride.Approved
LidoflazineThe therapeutic efficacy of Lidoflazine can be decreased when used in combination with Calcium Chloride.Experimental
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Calcium Chloride.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Calcium Chloride.Approved
Lipoic AcidCalcium Chloride can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Nutraceutical
LomefloxacinCalcium Chloride can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LomerizineThe therapeutic efficacy of Lomerizine can be decreased when used in combination with Calcium Chloride.Experimental
LoperamideThe therapeutic efficacy of Loperamide can be decreased when used in combination with Calcium Chloride.Approved
Magnesium sulfateThe therapeutic efficacy of Magnesium sulfate can be decreased when used in combination with Calcium Chloride.Approved, Investigational, Vet Approved
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Calcium Chloride.Approved, Investigational
MentholThe therapeutic efficacy of Menthol can be decreased when used in combination with Calcium Chloride.Approved
MethsuximideThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium Chloride.Approved
MethyclothiazideMethyclothiazide may decrease the excretion rate of Calcium Chloride which could result in a higher serum level.Approved
MetildigoxinCalcium Chloride may increase the arrhythmogenic activities of Metildigoxin.Experimental
MetolazoneMetolazone may decrease the excretion rate of Calcium Chloride which could result in a higher serum level.Approved
MibefradilThe therapeutic efficacy of Mibefradil can be decreased when used in combination with Calcium Chloride.Investigational, Withdrawn
MinocyclineThe serum concentration of Minocycline can be decreased when it is combined with Calcium Chloride.Approved, Investigational
MoxifloxacinCalcium Chloride can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NaftopidilThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium Chloride.Investigational
Nalidixic AcidCalcium Chloride can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NemonoxacinCalcium Chloride can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NicardipineThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium Chloride.Approved, Investigational
NifedipineThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Calcium Chloride.Approved
NiguldipineThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium Chloride.Experimental
NiludipineThe therapeutic efficacy of Niludipine can be decreased when used in combination with Calcium Chloride.Experimental
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Calcium Chloride.Approved, Investigational
NimesulideThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium Chloride.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium Chloride.Approved, Investigational
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium Chloride.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Chloride.Approved, Investigational
NorfloxacinCalcium Chloride can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NylidrinThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Calcium Chloride.Approved
OfloxacinCalcium Chloride can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OleandrinCalcium Chloride may increase the arrhythmogenic activities of Oleandrin.Experimental, Investigational
OtiloniumThe therapeutic efficacy of Otilonium can be decreased when used in combination with Calcium Chloride.Experimental, Investigational
OuabainCalcium Chloride may increase the arrhythmogenic activities of Ouabain.Approved
Oxolinic acidCalcium Chloride can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
OxytetracyclineThe serum concentration of Oxytetracycline can be decreased when it is combined with Calcium Chloride.Approved, Investigational, Vet Approved
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Calcium Chloride.Approved
ParicalcitolThe risk or severity of adverse effects can be increased when Calcium Chloride is combined with Paricalcitol.Approved, Investigational
PazufloxacinCalcium Chloride can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PefloxacinCalcium Chloride can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PenfluridolThe therapeutic efficacy of Penfluridol can be decreased when used in combination with Calcium Chloride.Experimental
PeruvosideCalcium Chloride may increase the arrhythmogenic activities of Peruvoside.Experimental
PinaveriumThe therapeutic efficacy of Pinaverium can be decreased when used in combination with Calcium Chloride.Approved
Pipemidic acidCalcium Chloride can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Piromidic acidCalcium Chloride can cause a decrease in the absorption of Piromidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PolythiazidePolythiazide may decrease the excretion rate of Calcium Chloride which could result in a higher serum level.Approved
PrenylamineThe therapeutic efficacy of Prenylamine can be decreased when used in combination with Calcium Chloride.Withdrawn
ProscillaridinCalcium Chloride may increase the arrhythmogenic activities of Proscillaridin.Experimental
PrulifloxacinCalcium Chloride can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
QuinethazoneQuinethazone may decrease the excretion rate of Calcium Chloride which could result in a higher serum level.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Calcium Chloride.Approved, Investigational
RosoxacinCalcium Chloride can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RufloxacinCalcium Chloride can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SeletracetamThe therapeutic efficacy of Seletracetam can be decreased when used in combination with Calcium Chloride.Investigational
SitafloxacinCalcium Chloride can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
Sodium glycerophosphateCalcium Chloride can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphate, monobasicCalcium Chloride can cause a decrease in the absorption of Sodium phosphate, monobasic resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SparfloxacinCalcium Chloride can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Strontium ranelateThe serum concentration of Strontium ranelate can be decreased when it is combined with Calcium Chloride.Approved, Withdrawn
Technetium Tc-99m etidronateThe serum concentration of Technetium Tc-99m etidronate can be decreased when it is combined with Calcium Chloride.Approved
Technetium Tc-99m medronateThe serum concentration of Technetium Tc-99m medronate can be decreased when it is combined with Calcium Chloride.Approved
TemafloxacinCalcium Chloride can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
TerodilineThe therapeutic efficacy of Terodiline can be decreased when used in combination with Calcium Chloride.Experimental
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Calcium Chloride.Approved, Vet Approved
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium Chloride.Investigational
TetrandrineThe therapeutic efficacy of Tetrandrine can be decreased when used in combination with Calcium Chloride.Experimental
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Calcium Chloride.Approved
Tiludronic acidThe serum concentration of Tiludronic acid can be decreased when it is combined with Calcium Chloride.Approved, Investigational, Vet Approved
Tolfenamic AcidThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium Chloride.Approved, Investigational
TranilastThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium Chloride.Approved, Investigational
TrichlormethiazideTrichlormethiazide may decrease the excretion rate of Calcium Chloride which could result in a higher serum level.Approved, Vet Approved
TriethylenetetramineThe serum concentration of Triethylenetetramine can be decreased when it is combined with Calcium Chloride.Approved, Investigational
TrimebutineThe therapeutic efficacy of Trimebutine can be decreased when used in combination with Calcium Chloride.Approved
TrimethadioneThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Calcium Chloride.Approved
TrovafloxacinCalcium Chloride can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
VerapamilThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium Chloride.Approved
VinpocetineThe therapeutic efficacy of Vinpocetine can be decreased when used in combination with Calcium Chloride.Investigational
WIN 55212-2The therapeutic efficacy of WIN 55212-2 can be decreased when used in combination with Calcium Chloride.Experimental
ZiconotideThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium Chloride.Approved
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Calcium Chloride.Approved
ZonisamideThe therapeutic efficacy of Zonisamide can be decreased when used in combination with Calcium Chloride.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Silvano Grosso, Kenneth E. Nelson, "Method for preparing liquid feed supplements containing calcium chloride." U.S. Patent US3962484, issued August, 1973.

US3962484
General References
Not Available
External Links
KEGG Compound
C08130
PubChem Compound
5284359
PubChem Substance
46507257
ChemSpider
23237
ChEBI
3312
ChEMBL
CHEMBL1200668
PharmGKB
PA448729
RxList
RxList Drug Page
Wikipedia
Calcium_chloride
ATC Codes
A11GB01 — Ascorbic acid (vit c) and calciumA12AA07 — Calcium chlorideB05XA07 — Calcium chlorideG04BA03 — Calcium chloride
AHFS Codes
  • 40:34.00* — Hemodialysis Solution
  • 40:12.00 — Replacement Preparations
MSDS
Download (74.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingPreventionScleral Contact Lenses1
1RecruitingTreatmentHead Neck Cancer1
1RecruitingTreatmentKeloid Scars1
1, 2CompletedOtherGlaucoma1
1, 2CompletedTreatmentArterial Hypotension / Arterial hypoxia1
1, 2RecruitingPreventionAtherosclerosis1
2Active Not RecruitingTreatmentCardiopulmonary Bypass / Surgery, Cardiac1
2CompletedTreatmentAcidosis, Respiratory / Shock, Hemorrhagic / Traumatic Shock1
2CompletedTreatmentBlood Loss,Surgical / General Surgery / Prostate Cancer1
2CompletedTreatmentCataracts1
2CompletedTreatmentDysmenorrhea / Endometriosis1
2CompletedTreatmentSymptomatic Focal Vitreomacular Adhesion1
2RecruitingPreventionPancreatoduodenectomy1
2TerminatedTreatmentCongestive Heart Failure (CHF)1
2, 3CompletedTreatmentGlaucoma1
3CompletedTreatmentCataracts2
3CompletedTreatmentColon Polyps / Colorectal Polyps / Crohn's Disease (CD) / Diverticulitis / Malignant Neoplasm of Colon / Rectal Carcinoma / Ulcerative Colitis (UC)1
3CompletedTreatmentContinuous ambulatory peritoneal dialysis therapy / Diabetes Mellitus (DM) / End Stage Renal Disease (ESRD)1
3CompletedTreatmentDiabetes Mellitus (DM) / ESRD1
3CompletedTreatmentParents2
3Enrolling by InvitationTreatmentAnaesthesia therapy1
3Unknown StatusTreatmentCongestive Heart Failure (CHF)1
4CompletedPreventionInflammatory Reaction1
4CompletedTreatmentAPD / Continuous ambulatory peritoneal dialysis therapy / Diabetes Mellitus (DM) / ESRD1
4CompletedTreatmentArthrocentesis / Pain / Temporomandibular Joint Dysfunction1
4CompletedTreatmentEmergency / Fluid Loss / Symptom Complex, Triple1
4Not Yet RecruitingTreatmentKetoacidosis, Diabetic1
4RecruitingSupportive CareMalnutrition1
4RecruitingTreatmentImpaired Renal Function1
4TerminatedPreventionDiastolic Dysfunction1
4TerminatedTreatmentDepression / Depression, Myalgia1
4Unknown StatusTreatmentTraumas1
4WithdrawnTreatmentClostridium Difficile Infection (CDI)1
Not AvailableCompletedTreatmentCataracts1
Not AvailableNot Yet RecruitingScreeningActual Impaired Fluid Volume1
Not AvailableRecruitingNot AvailablePain1
Not AvailableRecruitingTreatmentBiliary Atresia Intrahepatic Syndromic Form1
Not AvailableRecruitingTreatmentEnd Stage Renal Disease (ESRD)1
Not AvailableRecruitingTreatmentShock / Shock, Septic1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • American Regent
  • AstraZeneca Inc.
  • Baxter International Inc.
  • Cardinal Health
  • General Injectables and Vaccines Inc.
  • Hospira Inc.
  • J T Baker
  • Luitpold Pharmaceuticals Inc.
  • Physicians Total Care Inc.
  • Spectrum Pharmaceuticals
Dosage forms
FormRouteStrength
LiquidHemodialysis
Powder, for solutionIntraocular
SolutionIntraocular
SolutionIrrigation
Kit
Kit; solutionIntraocular
LiquidIntravenous100 mg
InjectionIntravenous100 mg/mL
InjectionIntravenous; Intraventricular100 mg/mL
InjectionParenteral100 mg/mL
Injection, solutionIntravenous100 mg/mL
Injection, solutionIntravenous20 mg/mL
Injection, solutionIntravenous; Intraventricular100 mg/mL
PowderHemodialysis12.32 g
PowderHemodialysis3.78 g
SolutionIntravenous100 mg
Powder, for solutionHemodialysis12.9 g
Powder, for solutionHemodialysis5.8 g
PowderHemodialysis6.1 g
PowderHemodialysis12.2 g
PowderHemodialysis7.45 g
PowderHemodialysis14.9 g
SolutionIntra-arterial
Injection, solutionIntraperitoneal
SolutionIntrathecal
InjectionIntrathecal
SolutionIntraperitoneal
SolutionOphthalmic
LiquidIntraperitoneal
SolutionHemodialysis; Intraperitoneal
LiquidIntraocular
Injection, emulsionIntravenous
SolutionIntravenous
LiquidIrrigation
Injection, solutionIntravenous
LiquidBuccal
SprayBuccal
SolutionHemodialysis
Kit; solutionIntraocular; Irrigation
Injection, solution, concentrateIntravenous
RinseDental
EmulsionIntravenous
Injection, solutionIntra-arterial
Solution
LiquidIntravenous
SolutionHemodialysis; Intravenous
Kit; solutionTopical
InjectionIntravenous
IrrigantIrrigation
AerosolOral
Prices
Unit descriptionCostUnit
SureStep Test 25 Strip Box31.92USD box
Calcium chloride powder0.44USD g
Calcium chloride 10% vial0.18USD ml
Calcium chloride granules0.1USD g
Calcium chloride 10% ampul0.07USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6077836No1997-06-202017-06-20Us
US6248726No1998-06-192018-06-19Us
US7084130No2001-11-292021-11-29Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)782 °CNot Available
water solubility0.745 g/mL (at 20 °C)Not Available
Predicted Properties
PropertyValueSource
logP-0.57ChemAxon
pKa (Strongest Acidic)-7ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9445
Blood Brain Barrier+0.975
Caco-2 permeable+0.6764
P-glycoprotein substrateNon-substrate0.9039
P-glycoprotein inhibitor INon-inhibitor0.9891
P-glycoprotein inhibitor IINon-inhibitor0.9866
Renal organic cation transporterNon-inhibitor0.9196
CYP450 2C9 substrateNon-substrate0.8116
CYP450 2D6 substrateNon-substrate0.717
CYP450 3A4 substrateNon-substrate0.7571
CYP450 1A2 substrateNon-inhibitor0.7506
CYP450 2C9 inhibitorNon-inhibitor0.8587
CYP450 2D6 inhibitorNon-inhibitor0.9306
CYP450 2C19 inhibitorNon-inhibitor0.8304
CYP450 3A4 inhibitorNon-inhibitor0.956
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9002
Ames testNon AMES toxic0.6808
CarcinogenicityCarcinogens 0.764
BiodegradationReady biodegradable0.6815
Rat acute toxicity1.9786 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9433
hERG inhibition (predictor II)Non-inhibitor0.9634
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as alkaline earth metal chlorides. These are inorganic compounds in which the largest halogen atom is Chlorine, and the heaviest metal atom is a lanthanide.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Alkaline earth metal salts
Sub Class
Alkaline earth metal chlorides
Direct Parent
Alkaline earth metal chlorides
Alternative Parents
Inorganic chloride salts / Inorganic calcium salts
Substituents
Alkaline earth metal chloride / Inorganic calcium salt / Inorganic chloride salt / Inorganic salt
Molecular Framework
Not Available
External Descriptors
inorganic chloride, calcium salt (CHEBI:3312)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Plays a role in the export of proteins that lack a signal peptide and are secreted by an alternative pathway. Binds two calcium ions per subunit. Binds one copper ion. Binding of one copper ion doe...
Gene Name
S100A13
Uniprot ID
Q99584
Uniprot Name
Protein S100-A13
Molecular Weight
11471.095 Da
References
  1. Sivaraja V, Kumar TK, Rajalingam D, Graziani I, Prudovsky I, Yu C: Copper binding affinity of S100A13, a key component of the FGF-1 nonclassical copper-dependent release complex. Biophys J. 2006 Sep 1;91(5):1832-43. Epub 2006 Jun 9. [PubMed:16766622]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:49